Skip to content

Study · Randomized controlled trial · n = 5,047 · 2024

2 results

Association of Baseline Factors With Glycemic Outcomes in GRADE: A Comparative Effectiveness Randomized Clinical Trial.

Garvey WT, Cohen RM, Butera NM, Kazemi EJ, Younes N, Rosin SP, Suratt CE, Ahmann A, Hollander PA, Krakoff J, Martin CL, Seaquist E, Steffes MW, Lachin JM

Diabetes care1 Apr 2024Cited by 12 (Europe PMC)

PMID38285957 (opens in a new tab)PMCIDPMC10973909 (opens in a new tab)DOI10.2337/dc23-1782 (opens in a new tab)PepBankPUB-38285957
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, liraglutide was superior at year 4 for the glycemic outcome after control for baseline factors.

    In plain wordsIn adults with type 2 diabetes on metformin, liraglutide did better than some other study drugs for blood sugar at year 4.

    Peptide
    Liraglutide
    Outcome
    Not applicableGlycemic outcome (HbA1c 7.0% or higher) at year 4, liraglutide versus other medications
    Study

    n = 5,047

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The superiority of glargine and liraglutide at year 4 persisted after multiple baseline factors were controlled for.
    1 context sentence
    Summary · context
    Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) participants (with type 2 diabetes diagnosed for <10 years, on metformin, and with HbA1c 6.8-8.5%; N = 5,047) were randomly assigned to a basal insulin (glargine), sulfonylurea (glimepiride), glucagon-like peptide 1…

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 02HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, no baseline factor was associated with differential effectiveness of the four medications by year 4.

    In plain wordsIn adults with type 2 diabetes, no baseline factor changed how well the four study drugs worked by year 4.

    Peptide
    Liraglutide
    Outcome
    No significant changeDifferential medication effectiveness by baseline factors at year 4
    Study

    n = 5,047

    Comparator
    Four medications compared
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    No factors were associated with differential effectiveness of the medications by year 4.
    1 context sentence
    Summary · context
    Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) participants (with type 2 diabetes diagnosed for <10 years, on metformin, and with HbA1c 6.8-8.5%; N = 5,047) were randomly assigned to a basal insulin (glargine), sulfonylurea (glimepiride), glucagon-like peptide 1…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01794143

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

GRADE Study Groupn = 7,850May 2013 to 30 Apr 2021

Type 2 Diabetes · Comparative Effectiveness of Glycemia-lowering Medications

Trial pageClinicalTrials.govUpdated 10 Feb 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.